Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat
about
Renal effects of dapagliflozin in patients with type 2 diabetesNephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?Beat it early: putative renoprotective haemodynamic effects of oral hypoglycaemic agentsSodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effectsEffect of Sodium-Glucose Cotransport Inhibition on Polycystic Kidney Disease Progression in PCK RatsEffects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis.A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin.Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy?Dapagliflozin for the treatment of type 2 diabetes: a review of the literatureA mathematical model of the rat nephron: glucose transport.Transient impairment of dynamic renal autoregulation in early diabetes mellitus in rats.Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease.Renoprotective effects of combined SGLT2 and ACE inhibitor therapy in diabetic Dahl S rats.Hyperfiltration and effect of nitric oxide inhibition on renal and endothelial function in humans with uncomplicated type 1 diabetes mellitus.Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitusSodium glucose cotransporter 2 inhibition in the diabetic kidney: an updateKnockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitusGlucagon-like peptide-1 receptor stimulation increases GFR and suppresses proximal reabsorption in the rat.A novel SGLT is expressed in the human kidney.Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN ratsPredicted consequences of diabetes and SGLT inhibition on transport and oxygen consumption along a rat nephron.Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney.SGLT-2 inhibitors and their potential in the treatment of diabetes.New therapeutic agents in diabetic nephropathy.Salt sensitivity of tubuloglomerular feedback in the early remnant kidneySGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control.Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial.Lowering plasma glucose concentration by inhibiting renal sodium-glucose cotransport.Dapagliflozin: a review of its use in patients with type 2 diabetes.The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension.Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.Are SGLT2 inhibitors reasonable antihypertensive drugs and renoprotective?Responses of renal hemodynamics and tubular functions to acute sodium-glucose cotransporter 2 inhibitor administration in non-diabetic anesthetized rats.Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta-analysis of randomized controlled trials.SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy: SGLT2 PROTEIN INHIBITION DECREASES RENAL LIPID ACCUMULATION, INFLAMMATION, AND THE DEVELOPMENT OF NEPHROPATHY IN DIABETIC MICE.Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies.Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.Renal Effects of SGLT-2 Inhibitors and Other Anti-diabetic Drugs: Clinical Relevance and Potential Risks.Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin.
P2860
Q24564811-D6DBA093-4456-4E3E-A7D9-57A149D53116Q26777994-68C20B74-3DB7-4FAF-986A-CE3397ED0984Q27010669-39AF121D-DB8A-41C8-94EC-14E94A305379Q28072765-743A464A-A222-49C3-8245-8B04F5AFB972Q30412552-3CBBFF44-29D0-4B97-BF79-E9F76618BC84Q32186373-872F97C5-9656-437C-8FF2-D6B79B421548Q33913060-E29FA5D0-EE50-48E4-872D-3E07A94D074DQ34579919-5C612764-C75F-4894-B51D-0696D3826DADQ34710819-F715840A-D1F8-4927-9980-7A67DF4B32BAQ35622486-B94951A0-1816-4973-A5E8-9DD5519A1B9FQ35738438-22E6351C-FA5B-462B-A43C-F8EB07D8885DQ35887931-687F8AC5-318B-492F-8F95-C87CC2FC58CFQ36004330-3977AB26-D056-45F4-9516-683FF915B1D7Q36312587-E5B10340-A363-43B1-B792-7E32CC6BB7ECQ36345951-27843255-60D4-4A75-BEA6-0ED7DC4F21E3Q36435496-386AAA5C-80C0-410C-AE13-578288140383Q36527897-399F99B5-F342-4AB7-B62D-A05E93B5959DQ36527908-0A57C854-C0D1-4BC8-BF6D-4344D8729401Q36706015-82D472D5-2383-426C-90A7-6F64FD53F6D4Q36852567-CC1CB5FA-5238-4243-87BE-0D4D33FADF5DQ37072443-1BFA3372-2D21-49AA-A193-22577007AB50Q37253944-85E4728A-2A99-486C-8D82-3B6742DA3D79Q37359631-64790342-133F-41B3-831F-4C1D66FF8D9CQ37559164-B827AA7A-1045-49F6-AEDD-0FB049C390A2Q37575446-D581B0CF-8637-495B-9365-EAA41EF4FADDQ37575455-999BCAFB-52B6-4CDC-9192-E797EED95301Q37679893-5627FAD0-5CC7-45C6-8C65-45AFD0DC0849Q37697744-A5F6483E-970E-4BAA-9B86-A8B1085FE613Q38201162-6A44F30E-F675-4639-8F2B-36A774C167D1Q38267346-A1AFC9DF-40AA-4023-964A-02631619A254Q38306298-2CABD3CE-C346-437D-9C3C-4582DDC7D0F0Q38330456-E131D3F0-6400-49ED-AB24-C4E54A6AD8CDQ38429845-DDF8E651-FEB9-4782-B8F9-E40262E3BDD2Q38607632-FB2D2590-42E6-4163-821A-52A20E6FEED2Q38940175-A4D42946-0D90-4751-8473-03105D1EA1A0Q38961637-4821F586-A2F5-40D9-9478-D8EBF6B53092Q39000587-0D204AD8-AC3D-4B1D-879A-C54215A0F0C8Q39017610-227B3675-AC17-4BB5-98DF-C652E58EED26Q39290337-9B5D408D-CCE5-43A1-8492-504BC4C1AF21Q39300057-D5BF3696-D0BA-4302-BC13-7F3743E7DA2F
P2860
Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Acute and chronic effects of S ...... tion in the early diabetic rat
@ast
Acute and chronic effects of S ...... tion in the early diabetic rat
@en
type
label
Acute and chronic effects of S ...... tion in the early diabetic rat
@ast
Acute and chronic effects of S ...... tion in the early diabetic rat
@en
prefLabel
Acute and chronic effects of S ...... tion in the early diabetic rat
@ast
Acute and chronic effects of S ...... tion in the early diabetic rat
@en
P2093
P2860
P1476
Acute and chronic effects of S ...... tion in the early diabetic rat
@en
P2093
Cynthia Miracle
Hadi Mansoury
Jean Whaley
Prabhleen Singh
Scott C Thomson
Volker Vallon
P2860
P304
P356
10.1152/AJPREGU.00357.2011
P50
P577
2011-09-21T00:00:00Z